Clinical trial
ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large…
NCT00140595 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00140595 |
|---|---|
| Title | ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 |
| Official title | Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1. |
| Lead sponsor | Lymphoma Study Association, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diffuse Large-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab, doxorubicin, cyclophosphamide |
| Enrollment | 380 |
| Start date | Dec 1, 2003 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Sep 1, 2005 |
| Last update posted | Mar 4, 2011 |
| Countries | Belgium, France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: